Home › Free Stock Grades › TXG
10x Genomics, Inc. (TXG) Stock Grade
TXG · Healthcare
C
Market Cap
$11.2B
P/E Ratio
—
Revenue Growth (YoY)
+5.3%
Net Margin
-6.8%
Return on Equity
—
Dividend Yield
None
About 10x Genomics, Inc.'s fundamentals
10x Genomics is a $11.2 billion biotechnology company that reported 5.3% year-over-year revenue growth but operated at a -6.8% net margin, resulting in a net loss for the latest annual period. Despite the accounting loss, the company generated positive free cash flow, indicating that its operational cash generation outpaced its reported losses. The company does not pay a dividend. Standard valuation metrics like P/E ratio and return on equity are not applicable due to the company's unprofitability.